TransMedics Group, Inc. (TMDX) Stock Analysis — Probabli.AI
AI-powered analysis for TMDX (TransMedics Group, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $63.30 · Market cap: $3.9B · AI outlook: Bullish
TransMedics Group has demonstrated exceptional growth potential and solid performance metrics, supported by strong product innovation and positive market outlooks. While recent stock volatility and patent-related risks remain a concern, the company's strategic initiatives and analyst confidence project a favorable growth trajectory. The stock offers significant upside in both medium and long-term…
Probabilistic 1-Year Outlook
- Bull 55% · Neutral 30% · Bear 15%
- 1-year price estimates — P10: $55 / P50: $127 / P90: $160
- TransMedics Group has demonstrated significant growth potential, as indicated by its stellar revenue growth and strong recent earnings performance. The analyst consensus is highly positive, underscoring broad support…
5-Year Outlook
- Bull 60% · Neutral 25% · Bear 15%
- 5-year price estimates — P10: $112 / P50: $230 / P90: $300
SWOT Highlights
- Strength: Unique and advanced product offerings in organ transplant logistics
- Strength: Strong revenue growth and EPS surprises
- Risk: Significant recent stock volatility
- Risk: Exposure to patent litigation
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
10 Wall Street analysts rate TMDX a BUY with a mean price target of $131.3.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
TMDX forecast details · TMDX sentiment details · TMDX insider activity
Recent saved forecast research
AI-generated research records, not evaluated investment results.
- TransMedics Group, Inc. (TMDX) — saved
TransMedics Group has demonstrated exceptional growth potential and solid performance metrics, supported by strong product innovation and positive market outlooks. While recent stock volatility and patent-related risks remain a concern, the
- TransMedics Group, Inc. (TMDX) — saved
TransMedics Group, Inc. (TMDX) features breakthrough innovations in healthcare, particularly in organ transportation, and is showing extraordinary revenue growth and financial performance. While recent market volatility linked to patent con
- TransMedics Group, Inc. (TMDX) — saved
TransMedics Group, Inc. is positioned as a high-growth firm in the medical device industry. With exceptional revenue growth rates, a strong product pipeline, and robust analyst endorsement, the stock shows strong upside potential in both sh
- TransMedics Group, Inc. (TMDX) — saved
TransMedics Group, Inc. exhibits a strong growth profile backed by outstanding revenue growth projections, repeated EPS surprises, and supportive analyst sentiment. The firm's innovative organ transplant technologies, coupled with recent FD
- TransMedics Group, Inc. (TMDX) — saved
TransMedics, with its strong fundamentals, innovative technologies, and leading position in organ preservation, has a distinctive growth trajectory. Despite temporary volatility, its revenue and earnings momentum reflects remarkable growth
- TransMedics Group, Inc. (TMDX) — saved
TransMedics Group, Inc. stands as an innovative leader in healthcare technologies, driven by robust revenue growth projections, a proven earnings track record, and favorable analyst sentiment. Tailwinds from strategic expansions, clinical t
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.